Cambridge Healthtech Institute’s Inaugural

Degraders & Molecular Glues: Beyond Oncology

Designing and Optimizing PROTACs and Glue Modalities for Diverse Therapeutic Indications

April 14, 2025

Protein degraders and molecular glues are being developed to disrupt protein-protein interactions and to hijack the ubiquitin-proteasome, lysosome, and autophagy systems for targeted protein degradation. While most of the hetero-bifunctional degraders like proteolysis-targeting chimeras (PROTACs) and monovalent degraders like molecular glues are being used to target cancer, there are some headwinds driving non-oncology indications as well. This inaugural symposium that focuses on applications of Degraders & Molecular Glues: Beyond Oncology will be followed by a two-part conference on Degraders & Molecular Glues which emphasizes the growing use of targeted protein degradation and induced proximity as a new therapeutic approach.

Coverage will likely include:

Emerging PROTACs, molecular glues, and new degrader modalities for non-oncology indications
Update on degraders in the clinic for inflammation, CNS, and more
Finding new ligases and mechanisms for targeted degradation in diverse therapeutic areas
Pursuing extracellular and hard-to-drug intracellular targets for degradation
Exploring degradation of RNA and lipids as drug targets for intervention

The deadline for priority consideration is September 27, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: